MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Effects of directional subthalamic deep brain stimulation on gait and balance in Parkinson Disease patients.

    S. Cherif, C. Olivier, J. Bourilhon, D. Bannier, D. Maltête, B. Lau, S. Derrey, E. Bardinet, C. Karachi, M. Welter (Paris, France)

    Objective: To assess the effects of directional STN-DBS on gait and balance in PD patients Background: STN-DBS is efficient to treat motor signs in PD…
  • 2022 International Congress

    Chronic Visceral Pain in Parkinson’s Disease and Link with White Matter Hyperintensities

    K. Rukavina, J. Staunton, M. Krbot Skoric, S. Rota, A. Rizos, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To explore whether there is a link between chronic visceral pain and white matter hyperintensities (WMH) on brain magnetic resonance imaging (MRI) in People…
  • 2022 International Congress

    GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease

    B. Guzman, N. Perez, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, A. Henriques, L. Rouviere, R. Maj (Lugano, Switzerland)

    Objective: Demonstrate the involvement of our structurally targeted allosteric regulator Parkinson’s disease (PD) candidate, GT-02287, in decreasing the CBE-induced neurotoxic effect and in restoring lysosomal…
  • 2022 International Congress

    Programming algorithm for the management of speech impairment in STN-DBS for Parkinson’s disease

    B. Swinnen, V. Lotfalla, J. Dijk, V. Odekerken, R. Schuurman, R. de Bie, M. Beudel (Amsterdam, Netherlands)

    Objective: To establish an evidence- and experience-based algorithm for the management of speech impairment (SI) in Parkinson’s disease (PD) patients treated with STN-DBS. Background: STN-DBS…
  • 2022 International Congress

    Unraveling the Potential of Specialized Allied Health Therapy in Parkinson’s Disease

    AH. Talebi, JHL. Ypinga, M. Munneke, B. Bloem, SKL. Darweesh (Nijmegen, Netherlands)

    Objective: To investigate discipline-specific effects of specialized Allied Health Therapy on the incidence of Parkinson’s Disease (PD)-related complications. Background: Specialized physiotherapy has been shown to…
  • 2022 International Congress

    Psychiatric evaluation according to Brief Psychiatric Rating Scale-Expanded in patients with Parkinson’s disease

    N. Ben Ali, M. Ben Mahmoud, E. Derbel, H. Jamoussi, S. Fray, M. Fredj (Tunis, Tunisia)

    Objective: The aim of the study was to evaluate psychiatric manifestations of Parkinson’s disease (PD) and to establish statistical links with sociodemographic and clinical PD…
  • 2022 International Congress

    Temporal dynamics and longitudinal predictors of apathy in Parkinson’s disease

    C. Le Heron, M. Macaskill, K. Horne, L. Livingstone, T. Melzer, D. Myall, T. Pitcher, J. Dalrymple-Alford, T. Anderson, S. Harrison (Christchurch, New Zealand)

    Objective: To determine how apathy varies across different disease stages of Parkinson’s disease (PD) and the longitudinal predictors of its development, using a large PD…
  • 2022 International Congress

    Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice

    C. Meng, G. Cui (Research Triangle Park, USA)

    Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…
  • 2022 International Congress

    Amantadine Is Effective Long-term in Parkinson’s Disease

    S. Park, BS. Jeon (Daejeon, Republic of Korea)

    Objective: This study aimed to investigate the long-term effectiveness of amantadine in patients with PD. Background: Amantadine has been used in the symptomatic treatment of…
  • 2022 International Congress

    CLINICAL CORRELATION OF VISUAL LEUKOARAIOSIS SCALES AND VOLUMETRIC ANALYSIS IN PATIENTS WITH ISCHEMIC CEREBRAL VASCULAR EVENT AND PARKINSON’S DISEASE.

    C. Cerda-Contreras (Monterrey, N.L., Mexico)

    Objective: Search for the clinical correlation of the most used leukoaraiosis scales in Parkinson's disease and ischemic stroke. Background: In recent decades, there has been…
  • « Previous Page
  • 1
  • …
  • 262
  • 263
  • 264
  • 265
  • 266
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley